48 related articles for article (PubMed ID: 35724530)
1. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Autonomic Nervous System Activity Using Spectral Analysis of Heart Rate Variability After Continuous Positive Airway Pressure (CPAP) Therapy in Patients With Sleep Apnea.
Vasilkova T; Fiore VF; Clum A; Wong A; Kabir N; Costello E; Crasta M
Cureus; 2024 Jan; 16(1):e51735. PubMed ID: 38187017
[TBL] [Abstract][Full Text] [Related]
3. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
4. Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Hardy TA; Aouad P; Barnett MH; Blum S; Broadley S; Carroll WM; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Van der Walt A; Martel K; Walker RA
Mult Scler J Exp Transl Clin; 2024; 10(1):20552173231226106. PubMed ID: 38222025
[TBL] [Abstract][Full Text] [Related]
5. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
Spiezia AL; Scalia G; Petracca M; Caliendo D; Moccia M; Fiore A; Cerbone V; Lanzillo R; Brescia Morra V; Carotenuto A
J Neurol; 2024 Apr; ():. PubMed ID: 38632126
[TBL] [Abstract][Full Text] [Related]
6. Comparing two relaxation procedures to ease fatigue in multiple sclerosis: a single-blind randomized controlled trial.
Garis G; Dettmers C; Hildebrandt A; Duning T; Hildebrandt H
Neurol Sci; 2023 Nov; 44(11):4087-4098. PubMed ID: 37698785
[TBL] [Abstract][Full Text] [Related]
7. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
Chang EH; Hardy TA
J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
[TBL] [Abstract][Full Text] [Related]
8. The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study).
Sancho-López A; Ruiz-Antorán B; Hernangómez TI; Ramírez-García A; Gómez-Estévez I; Sanabria-Cabrera J; Llop Rius R; Pedrós C; Campodonico D; Jiménez-Jorge S; García Luque A; Costa Frossad França L; Montané E; Aldea-Perona A; Téllez Lara N; Bosch Ferrer M; Rodriguez Jiménez C; Bonilla-Toyos E; Sabín Muñoz J; Avendaño-Solá C; Blasco Quilez MR; On Behalf Of The Realhes-Study Group
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892611
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
Rot U; Jerala M; Horvat Ledinek A; Brecl Jakob G
J Neurol; 2024 Jul; ():. PubMed ID: 38960947
[No Abstract] [Full Text] [Related]
10. S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review.
Constantinescu V; Haase R; Akgün K; Ziemssen T
Ther Adv Neurol Disord; 2022; 15():17562864221133163. PubMed ID: 36437849
[TBL] [Abstract][Full Text] [Related]
11. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.
Krbot Skorić M; Rogić D; Lapić I; Šegulja D; Habek M
Mult Scler Relat Disord; 2022 Jan; 57():103435. PubMed ID: 34920248
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Gilmartin CG; Hoyle N; Garjani A; Dixon T; Jos H; Paling D; Brownlee W; Tench C; Evangelou N
Mult Scler; 2024 Apr; 30(4-5):600-604. PubMed ID: 38323423
[TBL] [Abstract][Full Text] [Related]
14. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
15. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
